Bristol-Myers Squibb Co
BMY
Company Profile
Business description
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Contact
Route 206 and Province Line Road
Princeton
New JerseyNJ08543
USAT: +1 609 252-4621
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
34,100
Stocks News & Analysis
stocks
10 best US blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalisations look undervalued today.
personal-finance
US stock market outlook: tariffs are 2025's wild card
Macrodynamic tailwinds persist, but stocks are already priced to perfection. Will tariffs derail the market in 2025?
stocks
5 undervalued US stocks that crushed earnings
Names like Sony and GSK are still cheap despite impressive earnings beats for Q2 2024.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,833.50 | 20.80 | 0.24% |
| CAC 40 | 7,804.33 | 12.86 | 0.17% |
| DAX 40 | 23,987.56 | 186.76 | -0.77% |
| Dow JONES (US) | 42,866.87 | 105.11 | 0.25% |
| FTSE 100 | 8,853.08 | 20.80 | 0.24% |
| HKSE | 24,392.47 | 229.60 | 0.95% |
| NASDAQ | 19,714.99 | 123.75 | 0.63% |
| Nikkei 225 | 38,361.68 | 150.17 | 0.39% |
| NZX 50 Index | 12,617.78 | 53.36 | 0.42% |
| S&P 500 | 6,038.81 | 32.93 | 0.55% |
| S&P/ASX 200 | 8,606.80 | 19.60 | 0.23% |
| SSE Composite Index | 3,403.00 | 18.18 | 0.54% |